Chronic Hepatitis C Infection Clinical Trial
Official title:
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-II)
The purpose of this study is to evaluate the safety and efficacy of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) coadministered with ribavirin (RBV) in hepatitis C virus (HCV) genotype 1-infected adults with compensated cirrhosis.
During the treatment period of the study, participants received treatment with ABT-450/ritonavir/ABT-267 and ABT-333 coadministered with RBV for either 12 or 24 weeks. Upon completing the treatment period or premature discontinuation of the treatment period, participants entered a 48-week post-treatment period. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02216422 -
A Study to Evaluate Chronic Hepatitis C Infection in Cirrhotic Adults With Genotype 1b Infection
|
Phase 3 | |
Completed |
NCT02219503 -
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
|
Phase 3 | |
Completed |
NCT01700179 -
Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants
|
Phase 1 | |
Completed |
NCT02486406 -
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
|
Phase 2/Phase 3 | |
Completed |
NCT01221298 -
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
|
Phase 2 | |
Completed |
NCT01225380 -
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
|
Phase 2 | |
Completed |
NCT01715415 -
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
|
Phase 3 | |
Completed |
NCT01716585 -
A Study to Evaluate Chronic Hepatitis C Infection
|
Phase 3 | |
Completed |
NCT02065999 -
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
|
||
Completed |
NCT01453075 -
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
|
Phase 1 | |
Completed |
NCT01011166 -
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)
|
Phase 2 | |
Completed |
NCT00557583 -
Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults
|
Phase 1 | |
Terminated |
NCT01586325 -
A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients
|
Phase 1 | |
Recruiting |
NCT02583685 -
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
|
Phase 2 | |
Recruiting |
NCT02578693 -
Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
|
||
Completed |
NCT02576314 -
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
|
Phase 3 | |
Not yet recruiting |
NCT01835938 -
Clinical Investigation of Erlotinib as an HCV Entry Inhibitor
|
Phase 1/Phase 2 | |
Completed |
NCT01055821 -
Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients
|
Phase 2 | |
Completed |
NCT01854697 -
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before
|
Phase 3 | |
Completed |
NCT01833533 -
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
|
Phase 3 |